Lippincott Journals Subscribers, use your username or email along with your password to log in.
Registered users can save articles, searches, and manage email alerts.
All registration fields are required.
Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Friend's E-mail is Invalid
Your message has been successfully sent to your friend.
Oncology Times. 35(24):32-33, December 25th, 2013
Zoran Gatalica, MD, DSc, Executive Medical Director of Caris Life Sciences in Phoenix, Arizona, discusses his study of 1,400 patients with cancers of unknown primary site in whom 80 percent were found to have actionable molecular targets in a video interview at the European Cancer Congress.